Brepocitinib (PF-06700841) is a selective small molecule inhibitor with high potency for JAK1 and TYK2 kinases, and moderate activity against JAK2. It is widely used in preclinical research to investigate JAK/STAT signaling pathways in autoimmune and inflammatory disease models, both in vitro and in vivo.